Loading…

Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run

Introduction: A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial. Material and methods: Each participating centre received data from a suitable patient. Investigators...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2002-07, Vol.64 (1), p.65-73
Main Authors: Davis, J.Bernard, Reiner, Béatrice, Dusserre, Andrée, Giraud, Jean-Yves, Bolla, Michel
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13
cites cdi_FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13
container_end_page 73
container_issue 1
container_start_page 65
container_title Radiotherapy and oncology
container_volume 64
creator Davis, J.Bernard
Reiner, Béatrice
Dusserre, Andrée
Giraud, Jean-Yves
Bolla, Michel
description Introduction: A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial. Material and methods: Each participating centre received data from a suitable patient. Investigators were asked to plan and ‘treat’ the patient according to the protocol guidelines and return the data for evaluation of compliance. Results: The results show that compliance to the protocol guidelines was generally good. There were a few minor deviations in the dose and fractionation schedule, in the volume reduction for the booster dose and in the dose prescription point. None of these deviations will affect the outcome of the study. The most important observation is the large inter-centre variation in target volumes. Conclusions: The results of this study underlines the need for a strict definition of the target volume and the adoption of the ICRU 50 recommendations in future protocols.
doi_str_mv 10.1016/S0167-8140(02)00143-3
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72055869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167814002001433</els_id><sourcerecordid>72055869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EotPCI4C8QrBIsZ0_hw2qRi2MVFEBw9q6sW86Rkmc2k5FnocXxfMjWLKxF_7Ouef6EPKKs0vOePX-ezrqTPKCvWXiHWO8yLP8CVlxWTcZk7J-SlZ_kTNyHsJPxphgef2cnHEhmCzrekV-f52ht3GhEMLsYdRIXUfjDun13bftmkZvoadCNJxf0is67SAg3Ww2NMTZLHt2ciFmbkIP0T4ixV8R_Zg0Hox1ycjDtFA70gnizvXu3ur0GCLcI93mXxidfDJIWk01eG1HN8CHQwAzD8NC_Ty-IM866AO-PN0X5MfN9Xb9Obu9-7RZX91mWtRVzFqBVWGA5dCCKUUJxjSiEKXWyNCIincSoTVFJxtTFdAK2TStrozQncBc8_yCvDn6pkgPM4aoBhs09j2M6OagasHKUlZNAssjqFP24LFTk7cD-EVxpvbtqEM7av_1igl1aEflSff6NGBuBzT_VKc6EvDxCGBa89GiV0FbTKUY61FHZZz9z4g_sBmhPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72055869</pqid></control><display><type>article</type><title>Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run</title><source>ScienceDirect Freedom Collection</source><creator>Davis, J.Bernard ; Reiner, Béatrice ; Dusserre, Andrée ; Giraud, Jean-Yves ; Bolla, Michel</creator><creatorcontrib>Davis, J.Bernard ; Reiner, Béatrice ; Dusserre, Andrée ; Giraud, Jean-Yves ; Bolla, Michel ; EORTC</creatorcontrib><description>Introduction: A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial. Material and methods: Each participating centre received data from a suitable patient. Investigators were asked to plan and ‘treat’ the patient according to the protocol guidelines and return the data for evaluation of compliance. Results: The results show that compliance to the protocol guidelines was generally good. There were a few minor deviations in the dose and fractionation schedule, in the volume reduction for the booster dose and in the dose prescription point. None of these deviations will affect the outcome of the study. The most important observation is the large inter-centre variation in target volumes. Conclusions: The results of this study underlines the need for a strict definition of the target volume and the adoption of the ICRU 50 recommendations in future protocols.</description><identifier>ISSN: 0167-8140</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/S0167-8140(02)00143-3</identifier><identifier>PMID: 12208577</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Clinical trials ; Combined Modality Therapy ; Humans ; Male ; Multicenter Studies as Topic - standards ; Prostate cancer ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; Prostatic Neoplasms - surgery ; Protocol compliance ; Quality assurance ; Quality Control ; Radiotherapy Dosage ; Radiotherapy, High-Energy - standards</subject><ispartof>Radiotherapy and oncology, 2002-07, Vol.64 (1), p.65-73</ispartof><rights>2002 Elsevier Science Ireland Ltd</rights><rights>Copyright 2002 Elsevier Science Ireland Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13</citedby><cites>FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12208577$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Davis, J.Bernard</creatorcontrib><creatorcontrib>Reiner, Béatrice</creatorcontrib><creatorcontrib>Dusserre, Andrée</creatorcontrib><creatorcontrib>Giraud, Jean-Yves</creatorcontrib><creatorcontrib>Bolla, Michel</creatorcontrib><creatorcontrib>EORTC</creatorcontrib><title>Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run</title><title>Radiotherapy and oncology</title><addtitle>Radiother Oncol</addtitle><description>Introduction: A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial. Material and methods: Each participating centre received data from a suitable patient. Investigators were asked to plan and ‘treat’ the patient according to the protocol guidelines and return the data for evaluation of compliance. Results: The results show that compliance to the protocol guidelines was generally good. There were a few minor deviations in the dose and fractionation schedule, in the volume reduction for the booster dose and in the dose prescription point. None of these deviations will affect the outcome of the study. The most important observation is the large inter-centre variation in target volumes. Conclusions: The results of this study underlines the need for a strict definition of the target volume and the adoption of the ICRU 50 recommendations in future protocols.</description><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Multicenter Studies as Topic - standards</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Protocol compliance</subject><subject>Quality assurance</subject><subject>Quality Control</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy, High-Energy - standards</subject><issn>0167-8140</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqFkc1u1DAUhS0EotPCI4C8QrBIsZ0_hw2qRi2MVFEBw9q6sW86Rkmc2k5FnocXxfMjWLKxF_7Ouef6EPKKs0vOePX-ezrqTPKCvWXiHWO8yLP8CVlxWTcZk7J-SlZ_kTNyHsJPxphgef2cnHEhmCzrekV-f52ht3GhEMLsYdRIXUfjDun13bftmkZvoadCNJxf0is67SAg3Ww2NMTZLHt2ciFmbkIP0T4ixV8R_Zg0Hox1ycjDtFA70gnizvXu3ur0GCLcI93mXxidfDJIWk01eG1HN8CHQwAzD8NC_Ty-IM866AO-PN0X5MfN9Xb9Obu9-7RZX91mWtRVzFqBVWGA5dCCKUUJxjSiEKXWyNCIincSoTVFJxtTFdAK2TStrozQncBc8_yCvDn6pkgPM4aoBhs09j2M6OagasHKUlZNAssjqFP24LFTk7cD-EVxpvbtqEM7av_1igl1aEflSff6NGBuBzT_VKc6EvDxCGBa89GiV0FbTKUY61FHZZz9z4g_sBmhPg</recordid><startdate>200207</startdate><enddate>200207</enddate><creator>Davis, J.Bernard</creator><creator>Reiner, Béatrice</creator><creator>Dusserre, Andrée</creator><creator>Giraud, Jean-Yves</creator><creator>Bolla, Michel</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200207</creationdate><title>Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run</title><author>Davis, J.Bernard ; Reiner, Béatrice ; Dusserre, Andrée ; Giraud, Jean-Yves ; Bolla, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Multicenter Studies as Topic - standards</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Protocol compliance</topic><topic>Quality assurance</topic><topic>Quality Control</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy, High-Energy - standards</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Davis, J.Bernard</creatorcontrib><creatorcontrib>Reiner, Béatrice</creatorcontrib><creatorcontrib>Dusserre, Andrée</creatorcontrib><creatorcontrib>Giraud, Jean-Yves</creatorcontrib><creatorcontrib>Bolla, Michel</creatorcontrib><creatorcontrib>EORTC</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Davis, J.Bernard</au><au>Reiner, Béatrice</au><au>Dusserre, Andrée</au><au>Giraud, Jean-Yves</au><au>Bolla, Michel</au><aucorp>EORTC</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run</atitle><jtitle>Radiotherapy and oncology</jtitle><addtitle>Radiother Oncol</addtitle><date>2002-07</date><risdate>2002</risdate><volume>64</volume><issue>1</issue><spage>65</spage><epage>73</epage><pages>65-73</pages><issn>0167-8140</issn><eissn>1879-0887</eissn><abstract>Introduction: A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial. Material and methods: Each participating centre received data from a suitable patient. Investigators were asked to plan and ‘treat’ the patient according to the protocol guidelines and return the data for evaluation of compliance. Results: The results show that compliance to the protocol guidelines was generally good. There were a few minor deviations in the dose and fractionation schedule, in the volume reduction for the booster dose and in the dose prescription point. None of these deviations will affect the outcome of the study. The most important observation is the large inter-centre variation in target volumes. Conclusions: The results of this study underlines the need for a strict definition of the target volume and the adoption of the ICRU 50 recommendations in future protocols.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>12208577</pmid><doi>10.1016/S0167-8140(02)00143-3</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-8140
ispartof Radiotherapy and oncology, 2002-07, Vol.64 (1), p.65-73
issn 0167-8140
1879-0887
language eng
recordid cdi_proquest_miscellaneous_72055869
source ScienceDirect Freedom Collection
subjects Clinical trials
Combined Modality Therapy
Humans
Male
Multicenter Studies as Topic - standards
Prostate cancer
Prostatic Neoplasms - pathology
Prostatic Neoplasms - radiotherapy
Prostatic Neoplasms - surgery
Protocol compliance
Quality assurance
Quality Control
Radiotherapy Dosage
Radiotherapy, High-Energy - standards
title Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T12%3A15%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20assurance%20of%20the%20EORTC%20trial%2022911.%20A%20phase%20III%20study%20of%20post-operative%20external%20radiotherapy%20in%20pathological%20stage%20T3N0%20prostatic%20carcinoma:%20the%20dummy%20run&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=Davis,%20J.Bernard&rft.aucorp=EORTC&rft.date=2002-07&rft.volume=64&rft.issue=1&rft.spage=65&rft.epage=73&rft.pages=65-73&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/S0167-8140(02)00143-3&rft_dat=%3Cproquest_cross%3E72055869%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72055869&rft_id=info:pmid/12208577&rfr_iscdi=true